GlobeNewswire

World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer

Del

TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years.

PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy
Recent findings from the PACIFIC trial found that durvalumab demonstrates statistically significant and clinically meaningful improvement in overall survival (OS) compared with placebo for patients with Stage III, unresectable non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy (CRT).

According to Scott J. Antonia, M.D., Ph.D., department chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa and Professor of Oncologic Sciences at the University of South Florida College of Medicine, these results are significant, as PACIFIC is the first trial to show a survival advantage following CRT in this patient population.

“Results of PACIFIC provide compelling evidence for the unprecedented benefit of durvalumab treatment as the standard of care in this patient population,” said Dr. Antonia. “Durvalumab offers the first major advance in this disease setting in many years, offering new hope to patients with Stage III, unresectable NSCLC without progression after CRT.”

Read the full press release here.

Interim analysis of ALTA-1L demonstrates potential for brigatinib as first-line treatment option for ALK-positive non-small cell lung cancer
An interim analysis of the ALTA-1L study provided the first comparative data on the efficacy and safety of brigatinib versus crizotinib, the first-line standard of care comparator, in patients with anaplastic lymphoma kinase (ALK) inhibitor-naive ALK+ non-small cell lung cancer (NSCLC).

Lead investigator Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center, and team found one-year post-treatment, 67 percent of patients treated with brigatinib remained progression-free compared to 43 percent of those treated with crizotinib, and the risk of progression or death was reduced by 51 percent with brigatinib compared to crizotinib.

“Interim data shows brigatinib is set to become a first-line treatment option for ALK+ lung cancer,” said Dr. Camidge. “Even with only nine to 11 months of follow-up, the efficacy of brigatinib is clearly superior to crizotinib.”

Read the full press release here.

NELSON study shows CT screening for nodule volume management reduces lung cancer mortality by over fifty percent
Recent findings from Europe’s largest running lung cancer screening trial, the NELSON study, demonstrate that the use of computed tomography (CT) screening with a unique nodule management protocol led to a 26 percent reduction in deaths among lung cancer patients at eight years of study follow-up.

Harry J. De Koning, M.D., Ph.D., professor of Public Health & Screening Evaluation, Erasmus Medical Center, Rotterdam, Netherlands, and team initiated the study to assess the effect of CT screening, in combination with increasing screening intervals, on lung cancer mortality.

“These findings show that CT screenings are an effective way to assess and manage nodule volume in lung cancer patients, often leading to detection of suspicious nodules and subsequent surgical intervention, and can positively impact survival rates,” said Dr. De Koning. “These results can be used to inform and direct ongoing medical follow up and intervention for lung cancer patients.”

Read the full press release here.

Atezolizumab improves outcomes for small cell lung cancer when added to standard-of-care treatment
The IMpower133 study successfully met its co-primary endpoints, demonstrating that adding 1L atezolizumab to standard carboplatin and etoposide prolonged overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC), as compared to carboplatin and etoposide treatment alone.

According to presenter Stephen V. Liu, M.D., associate professor of medicine at Georgetown University and a member of the trial steering committee, these findings have the potential to change the current treatment landscape for ES-SCLC.

“The standard of care for extensive-stage small cell lung cancer has been unchanged for decades, which has contributed to unacceptably poor outcomes,” said Dr. Liu. “This is the first study in 30 years to show a significant improvement in survival in the first line treatment of this highly lethal disease. This is an exciting time in oncology, and we are thrilled to finally see real progress in the SCLC space.”

Read the full press release here.

LUME-Meso study shows nintedanib plus pemetrexed/cisplatin does not improve progression-free or overall survival in patients with malignant pleural mesothelioma of epithelioid subtype
Findings from the LUME-Meso study demonstrate that triple angiokinase inhibitor nintedanib combined with standard-of-care pemetrexed/cisplatin does not impact progression-free survival (PFS) and overall survival (OS) for unresectable malignant pleural mesothelioma (MPM) patients with epithelioid histology.

When Phase II data of LUME-Meso showed patients with epithelioid histology derived the greatest benefit from nintedanib added to pemetrexed/cisplatin in terms of improved PFS versus placebo and a trend towards improved OS, Giorgio V. Scagliotti, M.D., Ph.D., of the University of Turin’s Department of Oncology and S. Luigi Hospital, president of the International Association for the Study of Lung Cancer (IASLC), and team amended the Phase III protocol to focus solely on this subgroup.

“Unfortunately, the Phase III results of LUME-Meso did not confirm that nintedanib in combination with pemetrexed/cisplatin prolongs patients’ lives,” said Dr. Scagliotti. “However, the trial reaffirms the need for solid confirmatory studies, adequately sized, to challenge the standard of care in advanced malignant mesothelioma.”

Read the full press release here.

Livestreams of the daily press conferences are available here.

About the WCLC

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contacts:
Lisa Rivero  Becky Bunn, MSc
Vice President Public Relations Manager
lrivero@jpa.com| +1 617-657-1305 Becky.Bunn@IASLC.org | +1 720-254-9509

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

RCI Banque S.A.: Post Stabilisation Notice18.12.2018 15:55Pressemelding

PARIS, Dec. 18, 2018 (GLOBE NEWSWIRE) -- 18th December 2018 RCI Banque S.A. Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken in relation to RCI Banque S.A. GBP Fixed due 30th Oct 2023 because the transaction did not complete. Issuer: RCI Banque S.A. Guarantor (if any): NA Aggregate nominal amount: GBP Benchmark Description: Fixed due 30th Oct 2023 Offer price: na Stabilising Managers: HSBC, Lloyds, Natwest This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and condit

The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events18.12.2018 15:35Pressemelding

MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire – 2019 will kick off with what has become widely accepted as one of the most important blockchain conferences of the year. The North American Bitcoin Conference, sponsored by Keynote and part of the World Blockchain Forum, will take place Jan. 16-18, 2019, at the James L. Knight Center in Miami, Florida. This premier crypto conference, now in its seventh year, will draw cryptocurrency and blockchain leaders from all across the globe as they come together for this historical event. The North American Bitcoin Conference is the longest-running, most-attended finance conference for the blockchain and crypto industries, with each event attracting thousands of attendees. The 2019 conference will feature a lineup of more than 60 world-class presenters, including technology veterans and company founders who have collectively raised more than $18.1 billion in initial coin offerings (ICOs). Speakers that have been announced thus far

Inspirata Subsidiary, Artificial Intelligence in Medicine (AIM), Signs Contract with the National Cancer Institute (NCI) to Use Its E-Path Reporter Software for Reporting by U.S. Central Cancer Registries18.12.2018 15:06Pressemelding

The NCI has licensed AIM’s E-Path Reporter software for the last 15 years to provide an automated solution that enables cancer registries to more efficiently collect and report cancer incidence and survival data. Toronto, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Artificial Intelligence In Medicine Inc. (AIM), an Inspirata company, announced today that the National Cancer Institute (NCI) has extended its license agreement for AIM’s E-Path Reporter software. The software has been licensed for use within the SEER (Surveillance, Epidemiology and End Results) program, for 14 central registries and 286 major reporting hospitals and laboratories across the U.S. NCI supports cancer data collection and research through the SEER program and publishes cancer statistics for 20 U.S. geographic areas. The NCI requires participating cancer registries to collect data on cancer patient demographics, primary tumor site, tumor morphology and disease stage at diagnosis. The registries also must report on fir

Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services18.12.2018 14:30Pressemelding

Services and Capacity Increase with New Site Opening SAN DIEGO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening a new site in Suzhou, Jiangsu, China. The large amount of data now available from preclinical and clinical research requires specialized expertise in bioinformatics, big data analysis and dedicated storage facilities. CrownBio’s new site will focus on integrating the company’s experience in preclinical and translational research with cutting-edge digital technologies for the discovery of predictive biomarkers and the development of new and companion diagnostics. The Suzhou site will become CrownBio’s center of excellence for systems biology and clinical sample testing. Located at the heart of the Bi

Family of Constant-Current Dimmable Buck LED Drivers18.12.2018 11:00Pressemelding

1.5A, 3A Buck LED Drivers Target ISO26262 automotive and industrial applications MILPITAS, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AMS, the Analog Mixed-Signal division of ISSI, has introduced a family of switching buck LED Drivers for automotive and industrial applications. This family of highly integrated switching constant current buck LED Drivers are targeted for 12V/24V battery connected, space-constrained, electromagnetic (EMC) sensitive applications such as Headlight, Front and Rear Fog lights, Day time Running lights to name a few. The device family supports a wide DC voltage input range of 4.5V to 38V and outputs a 5% regulated current of 1.5A or 3A; depending on the particular device, see table. The integrated power MOSFET is configured to switch in the constant on-time mode delivering true average current. Switching at a frequency of up to 2MHz which is adjustable with an external resistor, these buck LED Drivers can use smaller output inductor and capacitor values thereby

John Charman Appointed Chief Executive Officer of Sompo Holdings Overseas Insurance Business and Nigel Frudd Appointed as Chief Executive Officer of Sompo International18.12.2018 10:13Pressemelding

Mr. Charman and Mr. Frudd to Join Sompo Holdings New Global Executive Committee PEMBROKE, Bermuda, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Sompo International Holdings Ltd. (Sompo International), a Bermuda-based specialty provider of property and casualty insurance and reinsurance, announced today that effective April 1, 2019, Mr. John Charman, currently Chairman of the Board of Directors and Chief Executive Officer of Sompo International, will be promoted to Chief Executive Officer of Overseas Insurance Business in Sompo Holdings, Inc. (Sompo Holdings). This segment of Sompo Holdings’ business currently represents more than 27% of Sompo Holdings Group’s adjusted profit, employing around 9,000 people in 30 countries and regions and is projected to have more than $10 billion in gross premiums by 2020. In such capacity, Mr. Charman will join the new Global Executive Committee of Sompo Holdings (Global ExCo) which will be established in April 2019 to provide expertise and input on group-wide st